Literature DB >> 30066862

Melatonin protects H9c2 cells against ischemia/reperfusion‑induced apoptosis and oxidative stress via activation of the Nrf2 signaling pathway.

Yan Zhang1, Baoguang Qiao1, Fei Gao1, Haifeng Wang1, Shaohua Miao1, Huan Zhao1.   

Abstract

Melatonin can protect against cardiac ischemia/reperfusion (I/R) injury in models in vitro and in vivo by regulating oxidative stress and apoptosis; however, the precise molecular mechanisms involved remain unclear. Nuclear factor erythroid 2‑related factor 2 (Nrf2) is a transcription factor, which has been associated with the regulation of oxidative stress by translocating to the nucleus. Therefore, the present study investigated whether activation of the Nrf2 signaling pathway may be responsible for the protective effects of melatonin on I/R‑injured cardiomyocytes. In the present study, H9c2 cells were subjected to simulated I/R (SIR) injury and pretreated with melatonin and/or Nrf2 small interfering RNA (siRNA). Cell viability was detected via Cell Counting kit‑8 assay, apoptosis was examined by caspase‑3 cleavage and activity analysis; oxidative stress levels were determined by specific activity analysis assays. In the present study, it was observed that SIR induced significant increases in apoptosis and oxidative stress, and enhanced Nrf2 expression within H9c2 cells. Pretreatment with melatonin partially reversed these alterations and promoted Nrf2 nuclear translocation. Transfection with Nrf2 siRNA inhibited the protective effects of melatonin on SIR‑induced H9c2 cells. These results indicated that melatonin may protect H9c2 cells against I/R injury by reducing apoptosis and oxidative stress; this effect may be mediated via activation of the Nrf2 signaling pathway. Collectively, the results of the present study may suggest melatonin as a potential therapeutic agent against cardiac I/R injury.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30066862     DOI: 10.3892/mmr.2018.9315

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

Review 1.  Melatonin as a protective agent in cardiac ischemia-reperfusion injury: Vision/Illusion?

Authors:  Puneet Kaur Randhawa; Manish Kumar Gupta
Journal:  Eur J Pharmacol       Date:  2020-08-26       Impact factor: 4.432

Review 2.  New insights into the role of melatonin in diabetic cardiomyopathy.

Authors:  Keming Huang; Xianling Luo; Yi Zhong; Li Deng; Jian Feng
Journal:  Pharmacol Res Perspect       Date:  2022-02

3.  Severe Hyperosmotic Stress Issues an ER Stress-Mediated "Death Sentence" in H9c2 Cells, with p38-MAPK and Autophagy "Coming to the Rescue".

Authors:  Konstantina-Eleni Bourouti; Christos Konstantaros; Catherine Gaitanaki; Ioanna-Katerina Aggeli
Journal:  Biomedicines       Date:  2022-06-15

Review 4.  Clinical Application of Melatonin in the Treatment of Cardiovascular Diseases: Current Evidence and New Insights into the Cardioprotective and Cardiotherapeutic Properties.

Authors:  Mohammad Hossein Pourhanifeh; Ehsan Dehdashtian; Azam Hosseinzadeh; Seyed Hashem Sezavar; Saeed Mehrzadi
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-14       Impact factor: 3.727

Review 5.  Pharmacological Protection against Ischemia-Reperfusion Injury by Regulating the Nrf2-Keap1-ARE Signaling Pathway.

Authors:  Bercis Imge Ucar; Gulberk Ucar; Sarmistha Saha; Brigitta Buttari; Elisabetta Profumo; Luciano Saso
Journal:  Antioxidants (Basel)       Date:  2021-05-21

6.  Epigallocatechin-3-gallate protects cardiomyocytes from hypoxia-reoxygenation damage via raising autophagy related 4C expression.

Authors:  Ping Liu; Jin Huang; Wanzhen Mei; Xingfang Zeng; Cheng Wang; Chuan Wen; Jing Xu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

7.  G protein-coupled receptor 39 activation alleviates oxidized low-density lipoprotein-induced macrophage inflammatory response, lipid accumulation and apoptosis by inducing A20 expression.

Authors:  Lu Chen; Zhengdong Fang; Xiaotian Wang; Xiaojie Sun; Xinbao Ge; Can Cheng; Hejie Hu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.